ID   RORA_HUMAN              Reviewed;         523 AA.
AC   P35398; P35397; P35399; P45445; Q495X4; Q96H83;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   16-APR-2014, sequence version 2.
DT   10-MAY-2017, entry version 180.
DE   RecName: Full=Nuclear receptor ROR-alpha;
DE   AltName: Full=Nuclear receptor RZR-alpha;
DE   AltName: Full=Nuclear receptor subfamily 1 group F member 1;
DE   AltName: Full=RAR-related orphan receptor A;
DE   AltName: Full=Retinoid-related orphan receptor-alpha;
GN   Name=RORA; Synonyms=NR1F1, RZRA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3), FUNCTION AS
RP   TRANSCRIPTION ACTIVATOR, DNA-BINDING, AND SUBUNIT.
RC   TISSUE=Retina, and Testis;
RX   PubMed=7926749; DOI=10.1101/gad.8.5.538;
RA   Giguere V., Tini M., Flock G., Ong E., Evans R.M., Otulakowski G.;
RT   "Isoform-specific amino-terminal domains dictate DNA-binding
RT   properties of ROR alpha, a novel family of orphan hormone nuclear
RT   receptors.";
RL   Genes Dev. 8:538-553(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), AND TISSUE SPECIFICITY.
RC   TISSUE=Umbilical vein endothelial cell;
RX   PubMed=7916608; DOI=10.1006/bbrc.1993.1976;
RA   Becker-Andre M., Andre E., Delamarter J.F.;
RT   "Identification of nuclear receptor mRNAs by RT-PCR amplification of
RT   conserved zinc-finger motif sequences.";
RL   Biochem. Biophys. Res. Commun. 194:1371-1379(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4).
RC   TISSUE=Kidney;
RA   Kaighin V.A., Martin A.L., Aronstam R.S.;
RT   "Isolation of cDNA coding for multiple human nuclear receptor
RT   clones.";
RL   Submitted (DEC-2010) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R.,
RA   Fahey J., Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G.,
RA   Johnson E., Jones C., Kamat A., Kaur A., Locke D.P., Madan A.,
RA   Munson G., Jaffe D.B., Lui A., Macdonald P., Mauceli E., Naylor J.W.,
RA   Nesbitt R., Nicol R., O'Leary S.B., Ratcliffe A., Rounsley S., She X.,
RA   Sneddon K.M.B., Stewart S., Sougnez C., Stone S.M., Topham K.,
RA   Vincent D., Wang S., Zimmer A.R., Birren B.W., Hood L., Lander E.S.,
RA   Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human
RT   chromosome 15.";
RL   Nature 440:671-675(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 4).
RC   TISSUE=Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION AS TRANSCRIPTION ACTIVATOR, INTERACTION WITH NCOR1,
RP   DNA-BINDING, AND SUBUNIT.
RX   PubMed=9328355; DOI=10.1210/mend.11.11.0002;
RA   Harding H.P., Atkins G.B., Jaffe A.B., Seo W.J., Lazar M.A.;
RT   "Transcriptional activation and repression by RORalpha, an orphan
RT   nuclear receptor required for cerebellar development.";
RL   Mol. Endocrinol. 11:1737-1746(1997).
RN   [8]
RP   FUNCTION AS TRANSCRIPTION ACTIVATOR, INTERACTION WITH MED1 AND NCOA2,
RP   AND MUTAGENESIS OF VAL-335 AND 510-LEU-PHE-511.
RX   PubMed=10478845; DOI=10.1210/mend.13.9.0343;
RA   Atkins G.B., Hu X., Guenther M.G., Rachez C., Freedman L.P.,
RA   Lazar M.A.;
RT   "Coactivators for the orphan nuclear receptor RORalpha.";
RL   Mol. Endocrinol. 13:1550-1557(1999).
RN   [9]
RP   FUNCTION IN MYOGENESIS, AND INTERACTION WITH EP300.
RX   PubMed=9862959; DOI=10.1093/nar/27.2.411;
RA   Lau P., Bailey P., Dowhan D.H., Muscat G.E.;
RT   "Exogenous expression of a dominant negative RORalpha1 vector in
RT   muscle cells impairs differentiation: RORalpha1 directly interacts
RT   with p300 and myoD.";
RL   Nucleic Acids Res. 27:411-420(1999).
RN   [10]
RP   FUNCTION AS TRANSCRIPTION ACTIVATOR, AND DNA-BINDING.
RX   PubMed=11554739; DOI=10.1006/bbrc.2001.5602;
RA   Sundvold H., Lien S.;
RT   "Identification of a novel peroxisome proliferator-activated receptor
RT   (PPAR) gamma promoter in man and transactivation by the nuclear
RT   receptor RORalpha1.";
RL   Biochem. Biophys. Res. Commun. 287:383-390(2001).
RN   [11]
RP   FUNCTION IN INFLAMMATION.
RX   PubMed=11252722; DOI=10.1093/embo-reports/kve007;
RA   Delerive P., Monte D., Dubois G., Trottein F., Fruchart-Najib J.,
RA   Mariani J., Fruchart J.C., Staels B.;
RT   "The orphan nuclear receptor ROR alpha is a negative regulator of the
RT   inflammatory response.";
RL   EMBO Rep. 2:42-48(2001).
RN   [12]
RP   FUNCTION IN TRIGLYCERIDE METABOLISM, AND DNA-BINDING.
RX   PubMed=11053433; DOI=10.1074/jbc.M004982200;
RA   Raspe E., Duez H., Gervois P., Fievet C., Fruchart J.C., Besnard S.,
RA   Mariani J., Tedgui A., Staels B.;
RT   "Transcriptional regulation of apolipoprotein C-III gene expression by
RT   the orphan nuclear receptor RORalpha.";
RL   J. Biol. Chem. 276:2865-2871(2001).
RN   [13]
RP   FUNCTION AS TRANSCRIPTION ACTIVATOR, UBIQUITINATION, AND MUTAGENESIS
RP   OF LYS-357; LEU-361; VAL-364 AND GLU-509.
RX   PubMed=14570920; DOI=10.1074/jbc.M308152200;
RA   Moraitis A.N., Giguere V.;
RT   "The co-repressor hairless protects RORalpha orphan nuclear receptor
RT   from proteasome-mediated degradation.";
RL   J. Biol. Chem. 278:52511-52518(2003).
RN   [14]
RP   INDUCTION BY HYPOXIA (ISOFORM 4).
RX   PubMed=14742449; DOI=10.1074/jbc.M313186200;
RA   Miki N., Ikuta M., Matsui T.;
RT   "Hypoxia-induced activation of the retinoic acid receptor-related
RT   orphan receptor alpha4 gene by an interaction between hypoxia-
RT   inducible factor-1 and Sp1.";
RL   J. Biol. Chem. 279:15025-15031(2004).
RN   [15]
RP   FUNCTION IN TRIGLYCERIDE METABOLISM, AND DNA-BINDING.
RX   PubMed=15790933; DOI=10.1161/01.ATV.0000163841.85333.83;
RA   Genoux A., Dehondt H., Helleboid-Chapman A., Duhem C., Hum D.W.,
RA   Martin G., Pennacchio L.A., Staels B., Fruchart-Najib J.,
RA   Fruchart J.C.;
RT   "Transcriptional regulation of apolipoprotein A5 gene expression by
RT   the nuclear receptor RORalpha.";
RL   Arterioscler. Thromb. Vasc. Biol. 25:1186-1192(2005).
RN   [16]
RP   FUNCTION IN TRIGLYCERIDE METABOLISM, AND DNA-BINDING.
RX   PubMed=15781255; DOI=10.1016/j.bbrc.2005.02.151;
RA   Lind U., Nilsson T., McPheat J., Stroemstedt P.E., Bamberg K.,
RA   Balendran C., Kang D.;
RT   "Identification of the human ApoAV gene as a novel RORalpha target
RT   gene.";
RL   Biochem. Biophys. Res. Commun. 330:233-241(2005).
RN   [17]
RP   FUNCTION IN CELL GROWTH, AND INDUCTION BY CELLULAR STRESS.
RX   PubMed=16462772; DOI=10.1038/sj.onc.1209314;
RA   Zhu Y., McAvoy S., Kuhn R., Smith D.I.;
RT   "RORA, a large common fragile site gene, is involved in cellular
RT   stress response.";
RL   Oncogene 25:2901-2908(2006).
RN   [18]
RP   PHOSPHORYLATION AT THR-183, FUNCTION, AND MUTAGENESIS OF THR-183.
RX   PubMed=17512500; DOI=10.1016/j.bbrc.2007.05.016;
RA   Lechtken A., Hoernig M., Werz O., Corvey N., Zoendorf I.,
RA   Dingermann T., Brandes R., Steinhilber D.;
RT   "Extracellular signal-regulated kinase-2 phosphorylates RORalpha4 in
RT   vitro.";
RL   Biochem. Biophys. Res. Commun. 358:890-896(2007).
RN   [19]
RP   FUNCTION IN HYPOXIA SIGNALING, INTERACTION WITH HIF1A, INDUCTION BY
RP   HYPOXIA, AND SUBCELLULAR LOCATION.
RX   PubMed=18658046; DOI=10.1161/ATVBAHA.108.171546;
RA   Kim E.J., Yoo Y.G., Yang W.K., Lim Y.S., Na T.Y., Lee I.K., Lee M.O.;
RT   "Transcriptional activation of HIF-1 by RORalpha and its role in
RT   hypoxia signaling.";
RL   Arterioscler. Thromb. Vasc. Biol. 28:1796-1802(2008).
RN   [20]
RP   FUNCTION, INTERACTION WITH FOXP3, SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, AND MUTAGENESIS OF 510-LEU-PHE-511.
RX   PubMed=18354202; DOI=10.4049/jimmunol.180.7.4785;
RA   Du J., Huang C., Zhou B., Ziegler S.F.;
RT   "Isoform-specific inhibition of ROR alpha-mediated transcriptional
RT   activation by human FOXP3.";
RL   J. Immunol. 180:4785-4792(2008).
RN   [21]
RP   FUNCTION AS TRANSCRIPTION ACTIVATOR, PHOSPHORYLATION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=18005000; DOI=10.1111/j.1471-4159.2007.05074.x;
RA   Duplus E., Gras C., Soubeyre V., Vodjdani G., Lemaigre-Dubreuil Y.,
RA   Brugg B.;
RT   "Phosphorylation and transcriptional activity regulation of retinoid-
RT   related orphan receptor alpha 1 by protein kinases C.";
RL   J. Neurochem. 104:1321-1332(2008).
RN   [22]
RP   SUMOYLATION AT LYS-240, AND MUTAGENESIS OF LYS-240 AND LYS-441.
RX   PubMed=19041634; DOI=10.1016/j.bbrc.2008.11.072;
RA   Hwang E.J., Lee J.M., Jeong J., Park J.H., Yang Y., Lim J.S.,
RA   Kim J.H., Baek S.H., Kim K.I.;
RT   "SUMOylation of RORalpha potentiates transcriptional activation
RT   function.";
RL   Biochem. Biophys. Res. Commun. 378:513-517(2009).
RN   [23]
RP   REVIEW ON FUNCTION.
RX   PubMed=19381306; DOI=10.1621/nrs.07003;
RA   Jetten A.M.;
RT   "Retinoid-related orphan receptors (RORs): critical roles in
RT   development, immunity, circadian rhythm, and cellular metabolism.";
RL   Nucl. Recept. Signal. 7:3-35(2009).
RN   [24]
RP   FUNCTION IN GLUCOSE METABOLISM REGULATION, AND IDENTIFICATION OF
RP   LIGANDS.
RX   PubMed=19965867; DOI=10.1074/jbc.M109.080614;
RA   Wang Y., Kumar N., Solt L.A., Richardson T.I., Helvering L.M.,
RA   Crumbley C., Garcia-Ordonez R.D., Stayrook K.R., Zhang X., Novick S.,
RA   Chalmers M.J., Griffin P.R., Burris T.P.;
RT   "Modulation of retinoic acid receptor-related orphan receptor alpha
RT   and gamma activity by 7-oxygenated sterol ligands.";
RL   J. Biol. Chem. 285:5013-5025(2010).
RN   [25]
RP   INTERACTION WITH NRIP1.
RX   PubMed=21628546; DOI=10.1177/0748730411401579;
RA   Poliandri A.H., Gamsby J.J., Christian M., Spinella M.J., Loros J.J.,
RA   Dunlap J.C., Parker M.G.;
RT   "Modulation of clock gene expression by the transcriptional
RT   coregulator receptor interacting protein 140 (RIP140).";
RL   J. Biol. Rhythms 26:187-199(2011).
RN   [26]
RP   FUNCTION IN T(H)17 CELLS DIFFERENTIATION, AND IDENTIFICATION OF
RP   LIGANDS.
RX   PubMed=21499262; DOI=10.1038/nature10075;
RA   Solt L.A., Kumar N., Nuhant P., Wang Y., Lauer J.L., Liu J.,
RA   Istrate M.A., Kamenecka T.M., Roush W.R., Vidovic D., Schuerer S.C.,
RA   Xu J., Wagoner G., Drew P.D., Griffin P.R., Burris T.P.;
RT   "Suppression of TH17 differentiation and autoimmunity by a synthetic
RT   ROR ligand.";
RL   Nature 472:491-494(2011).
RN   [27]
RP   INTERACTION WITH CRY1.
RX   PubMed=22170608; DOI=10.1038/nature10700;
RA   Lamia K.A., Papp S.J., Yu R.T., Barish G.D., Uhlenhaut N.H.,
RA   Jonker J.W., Downes M., Evans R.M.;
RT   "Cryptochromes mediate rhythmic repression of the glucocorticoid
RT   receptor.";
RL   Nature 480:552-556(2011).
RN   [28]
RP   METHYLATION AT LYS-38.
RX   PubMed=23063525; DOI=10.1016/j.molcel.2012.09.004;
RA   Lee J.M., Lee J.S., Kim H., Kim K., Park H., Kim J.Y., Lee S.H.,
RA   Kim I.S., Kim J., Lee M., Chung C.H., Seo S.B., Yoon J.B., Ko E.,
RA   Noh D.Y., Kim K.I., Kim K.K., Baek S.H.;
RT   "EZH2 generates a methyl degron that is recognized by the
RT   DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex.";
RL   Mol. Cell 48:572-586(2012).
RN   [29]
RP   REVIEW ON FUNCTION AND LIGANDS.
RX   PubMed=22789990; DOI=10.1016/j.tem.2012.05.012;
RA   Solt L.A., Burris T.P.;
RT   "Action of RORs and their ligands in (patho)physiology.";
RL   Trends Endocrinol. Metab. 23:619-627(2012).
RN   [30]
RP   VARIANT [LARGE SCALE ANALYSIS] SER-18 (ISOFORM 2).
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (1.63 ANGSTROMS) OF 271-523 IN COMPLEX WITH
RP   CHOLESTEROL, FUNCTION AS TRANSCRIPTION ACTIVATOR, IDENTIFICATION OF
RP   LIGANDS, MUTAGENESIS OF CYS-323; ALA-330; ALA-371; PHE-399; HIS-484
RP   AND TYR-507, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=12467577; DOI=10.1016/S0969-2126(02)00912-7;
RA   Kallen J.A., Schlaeppi J.-M., Bitsch F., Geisse S., Geiser M.,
RA   Delhon I., Fournier B.;
RT   "X-ray structure of the hRORalpha LBD at 1.63 A: structural and
RT   functional data that cholesterol or a cholesterol derivative is the
RT   natural ligand of RORalpha.";
RL   Structure 10:1697-1707(2002).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 271-523 IN COMPLEX WITH
RP   CHOLESTEROL SULFATE, MUTAGENESIS OF CYS-288; CYS-323; ALA-330; LYS-339
RP   AND GLU-509, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=14722075; DOI=10.1074/jbc.M400302200;
RA   Kallen J., Schlaeppi J.-M., Bitsch F., Delhon I., Fournier B.;
RT   "Crystal structure of the human RORalpha Ligand binding domain in
RT   complex with cholesterol sulfate at 2.2 A.";
RL   J. Biol. Chem. 279:14033-14038(2004).
CC   -!- FUNCTION: Nuclear receptor that binds DNA as a monomer to ROR
CC       response elements (RORE) containing a single core motif half-site
CC       5'-AGGTCA-3' preceded by a short A-T-rich sequence. Key regulator
CC       of embryonic development, cellular differentiation, immunity,
CC       circadian rhythm as well as lipid, steroid, xenobiotics and
CC       glucose metabolism. Considered to have intrinsic transcriptional
CC       activity, have some natural ligands like oxysterols that act as
CC       agonists (25-hydroxycholesterol) or inverse agonists (7-oxygenated
CC       sterols), enhancing or repressing the transcriptional activity,
CC       respectively. Recruits distinct combinations of cofactors to
CC       target genes regulatory regions to modulate their transcriptional
CC       expression, depending on the tissue, time and promoter contexts.
CC       Regulates genes involved in photoreceptor development including
CC       OPN1SW, OPN1SM and ARR3 and skeletal muscle development with
CC       MYOD1. Required for proper cerebellum development, regulates SHH
CC       gene expression, among others, to induce granule cells
CC       proliferation as well as expression of genes involved in calcium-
CC       mediated signal transduction. Regulates the circadian expression
CC       of several clock genes, including CLOCK, ARNTL/BMAL1, NPAS2 and
CC       CRY1. Competes with NR1D1 for binding to their shared DNA response
CC       element on some clock genes such as ARNTL/BMAL1, CRY1 and NR1D1
CC       itself, resulting in NR1D1-mediated repression or RORA-mediated
CC       activation of clock genes expression, leading to the circadian
CC       pattern of clock genes expression. Therefore influences the period
CC       length and stability of the clock. Regulates genes involved in
CC       lipid metabolism such as apolipoproteins APOA1, APOA5, APOC3 and
CC       PPARG. In liver, has specific and redundant functions with RORC as
CC       positive or negative modulator of expression of genes encoding
CC       phase I and phase II proteins involved in the metabolism of
CC       lipids, steroids and xenobiotics, such as CYP7B1 and SULT2A1.
CC       Induces a rhythmic expression of some of these genes. In addition,
CC       interplays functionally with NR1H2 and NR1H3 for the regulation of
CC       genes involved in cholesterol metabolism. Also involved in the
CC       regulation of hepatic glucose metabolism through the modulation of
CC       G6PC and PCK1. In adipose tissue, plays a role as negative
CC       regulator of adipocyte differentiation, probably acting through
CC       dual mechanisms. May suppress CEBPB-dependent adipogenesis through
CC       direct interaction and PPARG-dependent adipogenesis through
CC       competition for DNA-binding. Downstream of IL6 and TGFB and
CC       synergistically with RORC isoform 2, is implicated in the lineage
CC       specification of uncommitted CD4(+) T-helper (T(H)) cells into
CC       T(H)17 cells, antagonizing the T(H)1 program. Probably regulates
CC       IL17 and IL17F expression on T(H) by binding to the essential
CC       enhancer conserved non-coding sequence 2 (CNS2) in the IL17-IL17F
CC       locus. Involved in hypoxia signaling by interacting with and
CC       activating the transcriptional activity of HIF1A. May inhibit cell
CC       growth in response to cellular stress. May exert an anti-
CC       inflammatory role by inducing CHUK expression and inhibiting NF-
CC       kappa-B signaling. {ECO:0000269|PubMed:10478845,
CC       ECO:0000269|PubMed:11053433, ECO:0000269|PubMed:11252722,
CC       ECO:0000269|PubMed:11554739, ECO:0000269|PubMed:12467577,
CC       ECO:0000269|PubMed:14570920, ECO:0000269|PubMed:15781255,
CC       ECO:0000269|PubMed:15790933, ECO:0000269|PubMed:16462772,
CC       ECO:0000269|PubMed:17512500, ECO:0000269|PubMed:18005000,
CC       ECO:0000269|PubMed:18354202, ECO:0000269|PubMed:18658046,
CC       ECO:0000269|PubMed:19965867, ECO:0000269|PubMed:21499262,
CC       ECO:0000269|PubMed:7926749, ECO:0000269|PubMed:9328355,
CC       ECO:0000269|PubMed:9862959}.
CC   -!- SUBUNIT: Monomer. Interacts (via the DNA-binding domain) with
CC       HIF1A; the interaction enhances HIF1A transcription under hypoxia
CC       through increasing protein stability. Interacts with CEBPB; the
CC       interaction disrupts the interaction CEBPB:EP300. Interacts with
CC       the coactivators NCOA2, PPARGC1A (via LXXLL motif), EP300 and
CC       MED1. Interacts with the corepressor NCOR1. Interacts with MAGED1
CC       and CTNNB1. Interacts with CRY1 and PER2. Interacts (via AF-2
CC       motif) with PROX1 (By similarity). Interacts with NRIP1. Isoform 4
CC       interacts (via AF-2 motif) with isoform 1 of FOXP3 (via LXXLL
CC       motif). {ECO:0000250|UniProtKB:P51448,
CC       ECO:0000269|PubMed:10478845, ECO:0000269|PubMed:12467577,
CC       ECO:0000269|PubMed:14722075, ECO:0000269|PubMed:18354202,
CC       ECO:0000269|PubMed:18658046, ECO:0000269|PubMed:21628546,
CC       ECO:0000269|PubMed:22170608, ECO:0000269|PubMed:7926749,
CC       ECO:0000269|PubMed:9328355, ECO:0000269|PubMed:9862959}.
CC   -!- INTERACTION:
CC       Q9BZS1:FOXP3; NbExp=5; IntAct=EBI-11295807, EBI-983719;
CC       P14136:GFAP; NbExp=3; IntAct=EBI-748689, EBI-744302;
CC       P51843:NR0B1; NbExp=2; IntAct=EBI-748689, EBI-946109;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-
CC       ProRule:PRU00407, ECO:0000269|PubMed:18005000,
CC       ECO:0000269|PubMed:18354202, ECO:0000269|PubMed:18658046}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=Alpha-1;
CC         IsoId=P35398-2; Sequence=Displayed;
CC       Name=2; Synonyms=Alpha-2;
CC         IsoId=P35398-1; Sequence=VSP_053973;
CC         Note=Produced by alternative promoter usage. Region from 23 to
CC         71 inhibits DNA-binding and transactivation activity. Variant in
CC         position: 18:P->S (in a colorectal cancer sample, somatic
CC         mutation).;
CC       Name=3; Synonyms=Alpha-3;
CC         IsoId=P35398-3; Sequence=VSP_053975;
CC         Note=Produced by alternative splicing.;
CC       Name=4; Synonyms=Alpha-4;
CC         IsoId=P35398-4; Sequence=VSP_053974;
CC         Note=Produced by alternative promoter usage. Ref.2 (AAA02963)
CC         sequence is in conflict in position: 7:A->E. {ECO:0000305};
CC   -!- TISSUE SPECIFICITY: Widely expressed in a number of tissues.
CC       Expressed in both regulatory T-cells (Treg) and effector T-cells
CC       (Teff). {ECO:0000269|PubMed:18354202, ECO:0000269|PubMed:7916608}.
CC   -!- INDUCTION: Induced by oxidative stress and DNA damage. Isoform 4
CC       is induced by hypoxia (through transactivation by HIF1A and SP1),
CC       but not isoform 1. {ECO:0000269|PubMed:16462772,
CC       ECO:0000269|PubMed:18658046}.
CC   -!- DOMAIN: The AF-2 (activation function-2) motif is required for
CC       recruiting coregulators containing LXXLL motifs. {ECO:0000250}.
CC   -!- PTM: Phosphorylation by conventional PKCs in neurons inhibits
CC       transcriptional activity. Phosphorylated on Thr-183 by MAPK1/ERK1
CC       in vitro. {ECO:0000269|PubMed:17512500,
CC       ECO:0000269|PubMed:18005000}.
CC   -!- PTM: Sumoylated by SENP1 and SENP2. Sumoylation, promoted by
CC       PIAS2, PIAS3, PIAS4 but not PIAS1, enhances the transcriptional
CC       activity. Desumoylated by SENP1. {ECO:0000269|PubMed:19041634}.
CC   -!- PTM: Ubiquitinated, leading to its degradation by the proteasome.
CC       Proteasomal degradation is required for efficient transcriptional
CC       activity and is prevented by HR. {ECO:0000269|PubMed:14570920}.
CC   -!- PTM: Isoform 1: monomethylated at Lys-38 by EZH2, this creates a
CC       degron recognized by a DCX (DDB1-DCAF1/VPRBP-CUL4A-RBX1) E3
CC       ubiquitin ligase complex. {ECO:0000269|PubMed:14570920}.
CC   -!- SIMILARITY: Belongs to the nuclear hormone receptor family. NR1
CC       subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U04897; AAA62658.1; -; mRNA.
DR   EMBL; U04898; AAA62659.1; -; mRNA.
DR   EMBL; U04899; AAA62660.1; -; mRNA.
DR   EMBL; L14611; AAA02963.1; -; mRNA.
DR   EMBL; HQ692818; ADZ17329.1; -; mRNA.
DR   EMBL; AC009560; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC012404; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC022898; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC079068; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC087385; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC107241; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC107905; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471082; EAW77594.1; -; Genomic_DNA.
DR   EMBL; BC008831; AAH08831.1; -; mRNA.
DR   EMBL; BC100987; AAI00988.1; -; mRNA.
DR   EMBL; BC100988; AAI00989.1; -; mRNA.
DR   EMBL; BC100989; AAI00990.1; -; mRNA.
DR   EMBL; BC100990; AAI00991.1; -; mRNA.
DR   CCDS; CCDS10177.1; -. [P35398-2]
DR   CCDS; CCDS10179.1; -. [P35398-1]
DR   CCDS; CCDS45271.1; -. [P35398-4]
DR   PIR; A53196; A53196.
DR   PIR; A56856; A56856.
DR   PIR; B53196; B53196.
DR   PIR; C53196; C53196.
DR   RefSeq; NP_002934.1; NM_002943.3.
DR   RefSeq; NP_599022.1; NM_134260.2. [P35398-1]
DR   RefSeq; NP_599023.1; NM_134261.2. [P35398-2]
DR   RefSeq; NP_599024.1; NM_134262.2.
DR   UniGene; Hs.560343; -.
DR   PDB; 1N83; X-ray; 1.63 A; A=271-523.
DR   PDB; 1S0X; X-ray; 2.20 A; A=271-523.
DR   PDB; 4S15; X-ray; 1.90 A; A/B=269-523.
DR   PDBsum; 1N83; -.
DR   PDBsum; 1S0X; -.
DR   PDBsum; 4S15; -.
DR   ProteinModelPortal; P35398; -.
DR   SMR; P35398; -.
DR   BioGrid; 112022; 24.
DR   DIP; DIP-29938N; -.
DR   IntAct; P35398; 8.
DR   MINT; MINT-2855668; -.
DR   STRING; 9606.ENSP00000261523; -.
DR   BindingDB; P35398; -.
DR   ChEMBL; CHEMBL5868; -.
DR   DrugBank; DB04540; Cholesterol.
DR   DrugBank; DB01990; Cholesterol-Sulfate.
DR   GuidetoPHARMACOLOGY; 598; -.
DR   iPTMnet; P35398; -.
DR   PhosphoSitePlus; P35398; -.
DR   BioMuta; RORA; -.
DR   DMDM; 548814; -.
DR   PaxDb; P35398; -.
DR   PeptideAtlas; P35398; -.
DR   PRIDE; P35398; -.
DR   Ensembl; ENST00000261523; ENSP00000261523; ENSG00000069667. [P35398-1]
DR   Ensembl; ENST00000335670; ENSP00000335087; ENSG00000069667. [P35398-2]
DR   GeneID; 6095; -.
DR   KEGG; hsa:6095; -.
DR   UCSC; uc002agt.5; human. [P35398-2]
DR   CTD; 6095; -.
DR   DisGeNET; 6095; -.
DR   GeneCards; RORA; -.
DR   HGNC; HGNC:10258; RORA.
DR   HPA; CAB009861; -.
DR   MIM; 600825; gene.
DR   neXtProt; NX_P35398; -.
DR   OpenTargets; ENSG00000069667; -.
DR   PharmGKB; PA34630; -.
DR   eggNOG; KOG4216; Eukaryota.
DR   eggNOG; ENOG410XUGR; LUCA.
DR   GeneTree; ENSGT00870000136388; -.
DR   HOGENOM; HOG000010200; -.
DR   HOVERGEN; HBG106848; -.
DR   InParanoid; P35398; -.
DR   KO; K08532; -.
DR   OMA; NKPREVM; -.
DR   OrthoDB; EOG091G0649; -.
DR   TreeFam; TF319910; -.
DR   Reactome; R-HSA-1368082; RORA activates gene expression.
DR   Reactome; R-HSA-1368108; BMAL1:CLOCK,NPAS2 activates circadian gene expression.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-383280; Nuclear Receptor transcription pathway.
DR   Reactome; R-HSA-400253; Circadian Clock.
DR   Reactome; R-HSA-6785807; Interleukin-4 and 13 signaling.
DR   SignaLink; P35398; -.
DR   SIGNOR; P35398; -.
DR   ChiTaRS; RORA; human.
DR   EvolutionaryTrace; P35398; -.
DR   GeneWiki; RAR-related_orphan_receptor_alpha; -.
DR   GenomeRNAi; 6095; -.
DR   PRO; PR:P35398; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   Bgee; ENSG00000069667; -.
DR   CleanEx; HS_RORA; -.
DR   ExpressionAtlas; P35398; baseline and differential.
DR   Genevisible; P35398; HS.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0008013; F:beta-catenin binding; IEA:Ensembl.
DR   GO; GO:0001046; F:core promoter sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0008142; F:oxysterol binding; IDA:UniProtKB.
DR   GO; GO:0000977; F:RNA polymerase II regulatory region sequence-specific DNA binding; IDA:MGI.
DR   GO; GO:0004879; F:RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding; IEA:InterPro.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0003707; F:steroid hormone receptor activity; IEA:InterPro.
DR   GO; GO:0001223; F:transcription coactivator binding; IPI:UniProtKB.
DR   GO; GO:0001222; F:transcription corepressor binding; IPI:UniProtKB.
DR   GO; GO:0098531; F:transcription factor activity, direct ligand regulated sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0003700; F:transcription factor activity, sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0001525; P:angiogenesis; IMP:UniProtKB.
DR   GO; GO:0071456; P:cellular response to hypoxia; IMP:UniProtKB.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IEA:Ensembl.
DR   GO; GO:0036315; P:cellular response to sterol; IDA:UniProtKB.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IEA:Ensembl.
DR   GO; GO:0021930; P:cerebellar granule cell precursor proliferation; ISS:UniProtKB.
DR   GO; GO:0021702; P:cerebellar Purkinje cell differentiation; IEA:Ensembl.
DR   GO; GO:0046068; P:cGMP metabolic process; IEA:Ensembl.
DR   GO; GO:0032922; P:circadian regulation of gene expression; ISS:UniProtKB.
DR   GO; GO:0030522; P:intracellular receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0042692; P:muscle cell differentiation; IMP:UniProtKB.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; ISS:UniProtKB.
DR   GO; GO:0043124; P:negative regulation of I-kappaB kinase/NF-kappaB signaling; IMP:UniProtKB.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IMP:UniProtKB.
DR   GO; GO:0006809; P:nitric oxide biosynthetic process; IEA:Ensembl.
DR   GO; GO:0042753; P:positive regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:MGI.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0010575; P:positive regulation of vascular endothelial growth factor production; IMP:UniProtKB.
DR   GO; GO:2000188; P:regulation of cholesterol homeostasis; ISS:UniProtKB.
DR   GO; GO:0010906; P:regulation of glucose metabolic process; ISS:UniProtKB.
DR   GO; GO:0043030; P:regulation of macrophage activation; IEA:Ensembl.
DR   GO; GO:0008589; P:regulation of smoothened signaling pathway; ISS:UniProtKB.
DR   GO; GO:0019218; P:regulation of steroid metabolic process; ISS:UniProtKB.
DR   GO; GO:0060850; P:regulation of transcription involved in cell fate commitment; ISS:UniProtKB.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0072539; P:T-helper 17 cell differentiation; ISS:UniProtKB.
DR   GO; GO:0006367; P:transcription initiation from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0070328; P:triglyceride homeostasis; IMP:UniProtKB.
DR   GO; GO:0006805; P:xenobiotic metabolic process; ISS:UniProtKB.
DR   Gene3D; 3.30.50.10; -; 1.
DR   InterPro; IPR000536; Nucl_hrmn_rcpt_lig-bd.
DR   InterPro; IPR001723; Nuclear_hrmn_rcpt.
DR   InterPro; IPR003079; ROR_rcpt.
DR   InterPro; IPR001628; Znf_hrmn_rcpt.
DR   InterPro; IPR013088; Znf_NHR/GATA.
DR   Pfam; PF00104; Hormone_recep; 1.
DR   Pfam; PF00105; zf-C4; 1.
DR   PRINTS; PR01293; RORNUCRECPTR.
DR   PRINTS; PR00398; STRDHORMONER.
DR   PRINTS; PR00047; STROIDFINGER.
DR   SMART; SM00430; HOLI; 1.
DR   SMART; SM00399; ZnF_C4; 1.
DR   SUPFAM; SSF48508; SSF48508; 1.
DR   PROSITE; PS00031; NUCLEAR_REC_DBD_1; 1.
DR   PROSITE; PS51030; NUCLEAR_REC_DBD_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative promoter usage;
KW   Alternative splicing; Biological rhythms; Complete proteome;
KW   DNA-binding; Isopeptide bond; Metal-binding; Methylation; Nucleus;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome;
KW   Transcription; Transcription regulation; Ubl conjugation; Zinc;
KW   Zinc-finger.
FT   CHAIN         1    523       Nuclear receptor ROR-alpha.
FT                                /FTId=PRO_0000053512.
FT   DNA_BIND     73    138       Nuclear receptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00407}.
FT   ZN_FING      73     93       NR C4-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00407}.
FT   ZN_FING     109    133       NR C4-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00407}.
FT   REGION      139    271       Hinge.
FT   REGION      272    523       Ligand-binding.
FT   MOTIF       506    523       AF-2.
FT   COMPBIAS    166    169       Poly-Gln.
FT   MOD_RES      38     38       N6-methyllysine.
FT                                {ECO:0000269|PubMed:23063525}.
FT   MOD_RES     183    183       Phosphothreonine; by MAPK1.
FT                                {ECO:0000269|PubMed:17512500}.
FT   CROSSLNK    240    240       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000269|PubMed:19041634}.
FT   VAR_SEQ       1     66       MESAPAAPDPAASEPGSSGADAAAGSRETPLNQESARKSEP
FT                                PAPVRRQSYSSTSRGISVTKKTHTS -> MNEGAPGDSDLE
FT                                TEARVPWSIMGHCLRTGQARMSATPTPAGEGARRDELFGIL
FT                                QILHQCILSSGDAFVLTGVCCSWRQNGKPPYSQKEDKEVQT
FT                                GYMNA (in isoform 2).
FT                                {ECO:0000303|PubMed:7926749}.
FT                                /FTId=VSP_053973.
FT   VAR_SEQ       1     65       MESAPAAPDPAASEPGSSGADAAAGSRETPLNQESARKSEP
FT                                PAPVRRQSYSSTSRGISVTKKTHT -> MMYFVIAAMK
FT                                (in isoform 4).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:7916608,
FT                                ECO:0000303|Ref.3}.
FT                                /FTId=VSP_053974.
FT   VAR_SEQ      38     65       KSEPPAPVRRQSYSSTSRGISVTKKTHT -> SSSTCSSLS
FT                                RLFWSQLEHINWDGATAKNFINLREFFSFLLPALRK (in
FT                                isoform 3). {ECO:0000303|PubMed:7926749}.
FT                                /FTId=VSP_053975.
FT   MUTAGEN     183    183       T->A: Greatly increased transcriptional
FT                                activity. Decrease in repression by
FT                                NR1D1. {ECO:0000269|PubMed:17512500}.
FT   MUTAGEN     183    183       T->D,E: Some increase in transcriptional
FT                                activity. No change in repression by
FT                                NR1D1. {ECO:0000269|PubMed:17512500}.
FT   MUTAGEN     183    183       T->R: Attenuates transcriptional
FT                                activity. {ECO:0000269|PubMed:17512500}.
FT   MUTAGEN     183    183       T->V,I: Some increase in transcriptional
FT                                activity. {ECO:0000269|PubMed:17512500}.
FT   MUTAGEN     240    240       K->R: Loss of sumoylation.
FT                                {ECO:0000269|PubMed:19041634}.
FT   MUTAGEN     288    288       C->Q: Less effect on transcriptional
FT                                activity with cholesterol sulfate as
FT                                substrate as compared to cholesterol as
FT                                substrate. {ECO:0000269|PubMed:14722075}.
FT   MUTAGEN     323    323       C->L: About 60% loss of transcriptional
FT                                activity. {ECO:0000269|PubMed:12467577,
FT                                ECO:0000269|PubMed:14722075}.
FT   MUTAGEN     330    330       A->L: About 80% loss of transcriptional
FT                                activity. {ECO:0000269|PubMed:12467577,
FT                                ECO:0000269|PubMed:14722075}.
FT   MUTAGEN     335    335       V->R: Strongly decreases interaction with
FT                                NCOA2 and MED1.
FT                                {ECO:0000269|PubMed:10478845}.
FT   MUTAGEN     339    339       K->A: Complete loss of transcriptional
FT                                activity; when associated with A-507.
FT                                {ECO:0000269|PubMed:14722075}.
FT   MUTAGEN     357    357       K->A: Increased transcriptional activity.
FT                                No effect on protein degradation.
FT                                {ECO:0000269|PubMed:14570920}.
FT   MUTAGEN     361    361       L->F: Small reduction in transcriptional
FT                                activity. No protein degradation.
FT                                {ECO:0000269|PubMed:14570920}.
FT   MUTAGEN     364    364       V->G: Greatly reduced transcriptional
FT                                activity. Protects from protein
FT                                degradation.
FT                                {ECO:0000269|PubMed:14570920}.
FT   MUTAGEN     371    371       A->Q: Almost total loss of
FT                                transcriptional activity.
FT                                {ECO:0000269|PubMed:12467577}.
FT   MUTAGEN     399    399       F->W: Slight loss of transcriptional
FT                                activity. {ECO:0000269|PubMed:12467577}.
FT   MUTAGEN     441    441       K->R: No effect on sumoylation.
FT                                {ECO:0000269|PubMed:19041634}.
FT   MUTAGEN     484    484       H->W: Almost total loss of
FT                                transcriptional activity.
FT                                {ECO:0000269|PubMed:12467577}.
FT   MUTAGEN     507    507       Y->A: Complete loss of transcriptional
FT                                activity; when associated with A-339.
FT                                {ECO:0000269|PubMed:12467577}.
FT   MUTAGEN     507    507       Y->F: About 40% loss of transcriptional
FT                                activity. {ECO:0000269|PubMed:12467577}.
FT   MUTAGEN     509    509       E->K: Abolishes transcriptional activity.
FT                                Protects from protein degradation.
FT                                {ECO:0000269|PubMed:14570920,
FT                                ECO:0000269|PubMed:14722075}.
FT   MUTAGEN     510    511       LF->AA: Decreases interaction with NCOA2.
FT                                Loss of interaction with FOXP3.
FT                                {ECO:0000269|PubMed:10478845,
FT                                ECO:0000269|PubMed:18354202}.
FT   CONFLICT    368    368       M -> V (in Ref. 2; AAA02963).
FT                                {ECO:0000305}.
FT   CONFLICT    466    466       I -> M (in Ref. 2; AAA02963).
FT                                {ECO:0000305}.
FT   HELIX       271    286       {ECO:0000244|PDB:1N83}.
FT   HELIX       292    297       {ECO:0000244|PDB:1N83}.
FT   TURN        298    300       {ECO:0000244|PDB:1N83}.
FT   HELIX       305    313       {ECO:0000244|PDB:1N83}.
FT   HELIX       316    340       {ECO:0000244|PDB:1N83}.
FT   TURN        342    346       {ECO:0000244|PDB:1N83}.
FT   HELIX       349    367       {ECO:0000244|PDB:1N83}.
FT   HELIX       368    371       {ECO:0000244|PDB:1N83}.
FT   TURN        374    377       {ECO:0000244|PDB:1N83}.
FT   STRAND      378    381       {ECO:0000244|PDB:1N83}.
FT   STRAND      384    386       {ECO:0000244|PDB:1N83}.
FT   HELIX       388    394       {ECO:0000244|PDB:1N83}.
FT   HELIX       397    411       {ECO:0000244|PDB:1N83}.
FT   TURN        412    414       {ECO:0000244|PDB:4S15}.
FT   HELIX       417    428       {ECO:0000244|PDB:1N83}.
FT   HELIX       439    460       {ECO:0000244|PDB:1N83}.
FT   HELIX       466    494       {ECO:0000244|PDB:1N83}.
FT   HELIX       496    502       {ECO:0000244|PDB:1N83}.
FT   HELIX       505    510       {ECO:0000244|PDB:1N83}.
SQ   SEQUENCE   523 AA;  58975 MW;  0FA43BBCE6E28DC7 CRC64;
     MESAPAAPDP AASEPGSSGA DAAAGSRETP LNQESARKSE PPAPVRRQSY SSTSRGISVT
     KKTHTSQIEI IPCKICGDKS SGIHYGVITC EGCKGFFRRS QQSNATYSCP RQKNCLIDRT
     SRNRCQHCRL QKCLAVGMSR DAVKFGRMSK KQRDSLYAEV QKHRMQQQQR DHQQQPGEAE
     PLTPTYNISA NGLTELHDDL SNYIDGHTPE GSKADSAVSS FYLDIQPSPD QSGLDINGIK
     PEPICDYTPA SGFFPYCSFT NGETSPTVSM AELEHLAQNI SKSHLETCQY LREELQQITW
     QTFLQEEIEN YQNKQREVMW QLCAIKITEA IQYVVEFAKR IDGFMELCQN DQIVLLKAGS
     LEVVFIRMCR AFDSQNNTVY FDGKYASPDV FKSLGCEDFI SFVFEFGKSL CSMHLTEDEI
     ALFSAFVLMS ADRSWLQEKV KIEKLQQKIQ LALQHVLQKN HREDGILTKL ICKVSTLRAL
     CGRHTEKLMA FKAIYPDIVR LHFPPLYKEL FTSEFEPAMQ IDG
//
